Semirational design of (North)-methanocarba nucleosides as dual acting A1 and A3 adenosine receptor agonists: Novel prototypes for cardioprotection

Journal of Medicinal Chemistry

Volumn 48, Issue 26, 2005, Pages 8103-8107

  Jacobson, Kenneth A ^a   Gao, Zhan Guo ^a   Tchilibon, Susanna ^a   Duong, Heng T ^a   Joshi, Bhalchandra V ^a   Sonin, Dmitry ^b   Liang, Bruce T ^b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 N CYCLOPENTYLADENOSINE; 6 N CYCLOPENTYLADENOSINE DERIVATIVE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A2 RECEPTOR; ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE DERIVATIVE; METHANOCARBANUCLEOSIDE; N METHANOCARBA 2 CHLORO 5' URONAMIDE; NORBORNENE DERIVATIVE; NUCLEOSIDE; UNCLASSIFIED DRUG; ADENOSINE; ADENOSINE A2A RECEPTOR; ADENOSINE A3 RECEPTOR; CARDIOTONIC AGENT; DRUG DERIVATIVE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; NONHUMAN; RECEPTOR AFFINITY; RECEPTOR SENSITIVITY; ANIMAL; CHO CELL; DRUG EFFECT; DRUG POTENTIATION; HAMSTER; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; METABOLISM; MOUSE; REPERFUSION INJURY; SYNTHESIS;

ADENOSINE; ANIMALS; CARDIOTONIC AGENTS; CHO CELLS; CRICETINAE; DRUG DESIGN; HUMANS; MICE; MYOCARDIAL INFARCTION; RECEPTOR, ADENOSINE A1; RECEPTOR, ADENOSINE A2A; RECEPTOR, ADENOSINE A3; REPERFUSION INJURY; VENTRICULAR FUNCTION, LEFT;

EID: 29744468596     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050726b     Document Type: Article

References (28)

1. Fredholm, B. B.; IJzerman, A. P.; Jacobson, K. A.; Klotz, K.-N.; Linden, J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 2001, 53, 527-552.
2. Yao, L.; Burbiel, J. C.; Maass, A.; Müller, C. E. Adenosine receptor agonists: from basic medicinal chemistry to clinical development. Expert Opin. Emerging Drugs. 2003, 8, 537-576.
3. 3 receptor may mediate the protection afforded by preconditioning in the isolated rabbit heart. Cardiovasc. Res. 1994, 28, 1057-1061.
4. 3 receptor: sustained cardioprotection, Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 6995-6999.
5. 3 receptors reduce ischemic myocardial injury. Am. J. Physiol. Heart Circ. Physiol. 2003, 285, H2780.
6. Peart, J.; Flood, A.; Linden, J.; Matherne, G. P.; Headrick, J. P. Adenosine-mediated cardioprotection in ischemic-reperfused mouse heart. J Cardiovasc Pharmacol. 2002, 39, 117-129.
7. 3 receptor activation protects the myocardium from reperfusion/ reoxygenation injury. Am. J. Physiol. Heart Circ. Physiol. 2002, 283, H1307-H1313.
8. 3 adenosine receptors decrases heart rate, preserves energetics, and protects ischemic hearts. Am. J. Physiol. Heart Circ. Physiol. 2002, 283, H1562-1568.
9. Parsons, M.; Young, L.; Lee, J.-E.; Jacobson, K. A.; Liang, B. T. Distinct cardioprotective effects of adenosine mediated by differential coupling of receptor subtypes to phospholipases C and D. FASEB J. 2000, 14, 1423-1431.
10. Shneyvays, V.; Leshem, D.; Zinman, T.; Mamedova, L. K.; Jacobson, K. A.; Shainberg, A. Role of adenosine A1 and A3 receptors in regulation of cardiomyocyte homeostasis after mitochondrial respiratory chain injury, Am. J. Physiol. Heart Circ. Physiol. 2005, 288, H2792-H2801.
11. 3 receptors in protection of isolated human atrial muscle against simulated ischaemia. Cardiovasc. Res. 1997, 36, 552-59.
12. 1 adenosine receptor. Basic Res. Cardiol. 2001, 96, 487-96.
13. 3 receptor-induced delayed cardioprotection in mouse. Am. J. Physiol. Heart Circ. Physiol. 2003, 285, H434-441.
14. Fredholm, B. B.; Chen, J. F.; Cunha, R. A.; Svenningsson, P.; Vaugeois, J. M. Adenosine and brain function. Int. Rev. Neurobiol. 2005, 63, 191-270.
15. 1 receptor agonist. Eur. J. Pharmacol. 1999, 369, 313-317.
16. 3 adenosine receptor agonists J. Biol. Chem. 2000, 275, 30272-30279.
17. 6-carboxamido-derivatives of adenosine-5′-N-ethyluronamide (NECA) as A1 and A3 adenosine receptor agonists. J. Med. Chem. 1998, 41, 3174-3185.
18. 3 receptor. J. Med. Chem. 2002, 45, 420-429.
19. Cappellacci, L.; Franchetti, P.; Pasqualini, M.; Petrelli, R.; Vita, P.; Lavecchia, A.; Novellino, E.; Costa, B.; Martini, C.; Klotz, K. N.; Grifantini, M. Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists. J. Med. Chem. 2005, 48, 1550-1562.
20. Lipinski, C.; Hopkins, A. Navigating chemical space for biology and medicine. Nature 2004, 432, 855-861.
21. 3 adenosine receptor agonists. J. Med. Chem. 2005, 48, 1745-1758.
22. 3 adenosine receptor activation: Nucleoside ligands at the agonist/antagonist boundary. J. Med. Chem. 2002, 45, 4471-4484.
23. 3 adenosine receptors. Biochem. Pharmacol. 2003, 65, 1675-1684.
24. 6-(2-phenylethyl)adenosine derivatives as potent ligands. Bioorg. Med. Chem. 2004, 12, 2021-2034.
25. 3 adenosine receptor agonists. J. Org. Chem. 2005, 70, 439-447.
26. Ichinose, F.; Bloch K. D.; Wu, J. C.; Hataishi, R.; Aretz, H. T.; Picard, M. H.; Scherrer-Crosbie, M. Pressure overload-induced LV hypertrophy and dysfunction in mice are exacerbated by congenital NOS3 deficiency. Am. J. Physiol. Heart Circ. Physiol. 2004, 286, H1070-H1075.
27. Hinsehen, A. K.; Rose Meyer, R. B.; Headrick, J. P. Adenosine receptor subtypes mediating coronary vasodilation in rat hearts. J Cardiovasc Pharmacol. 2003, 41, 73-80.
28. Klotz, K.-N.; Hessling, J.; Hegler, J.; Owman, C.; Kull, B.; Fredholm, B. B.; Lohse, M. J. Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells. Naunyn-Schmiedeberg's Arch. Pharmacol 1998, 357, 1-9.